Please login to the form below
Advate
This page shows the latest Advate news and features for those working in and with pharma, biotech and healthcare.
Shire wins FDA approval for haemophilia dosing software
The web-based myPKFiT supports the pharma firm's Advate treatment. US regulators have approved Shire’s new web-based dosing software for its recombinant Factor VIII haemophilia A treatment Advate. ... A version of the myPKFiT for Advate software has
Latest news
-
Shire claims EU approval for haemophilia A drug Adynovi
The European Commission has approved Shire’s haemophilia A therapy Adynovi, a new long-acting version of its long-established Advate product.
-
Shire wins CHMP backing for Adynovi
The injectable is a new form of Advate - a haemophilia A treatment Shire acquired from Baxalta in a $32bn takeover - and offers twice-weekly prophylactic use as well as on-demand
-
Sobi looks to real-world trial to push Elocta take-up
to wrest market share from established haemophilia A therapies such as Shire/Baxalta's Advate (octocog alfa).
-
Baxalta agrees to $32bn Shire takeover
The merger will couple Baxalta's haemophilia franchise - including its big selling Advate product for haemophilia A and long-acting follow-up BAX-855 which is nearing the market- with Shire
-
First von Willebrand disease therapy heads new FDA approvals
Last month it secured FDA approval for long-acting haemophilia A therapy Adynovate (formerly BAX 855), a follow-up to its big-selling Advate brand.
More from news
Approximately 3 fully matching, plus 21 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
